Singapore Clinical Trial: A Randomized, Open-Label, Phase 3 Study of Rinatabart Sesutecan (Rina-S) Plus Standard of Care Versus Standard of Care as Maintenance Treatment After 2L Platinum-Based Doublet Chemotherapy in Participants With Recurrent Platinum- Sensitive Ovarian Cancer (PSOC)

Singapore, Sept. 21 -- The Health Sciences Authority received information related to the study titled 'A Randomized, Open-Label, Phase 3 Study of Rinatabart Sesutecan (Rina-S) Plus Standard of Care Ve... Read More

Singapore Clinical Trial: An Open-label, Randomized, Controlled Phase 3 Study of Disitamab Vedotin in Combination with Pembrolizumab Versus Chemotherapy in Subjects with Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma that Expresses HER2 (IHC 1+ and Greater)

Singapore, Sept. 21 -- The Health Sciences Authority received information related to the study titled 'An Open-label, Randomized, Controlled Phase 3 Study of Disitamab Vedotin in Combination with Pemb... Read More

Singapore Clinical Trial: An Open-label, Randomized, Controlled Phase 3 Study of Disitamab Vedotin in Combination with Pembrolizumab Versus Chemotherapy in Subjects with Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma that Expresses HER2 (IHC 1+ and Greater)

Singapore, Sept. 21 -- The Health Sciences Authority received information related to the study titled 'An Open-label, Randomized, Controlled Phase 3 Study of Disitamab Vedotin in Combination with Pemb... Read More

Singapore Clinical Trial: A Randomized, Open-label, Phase 3 Study of Rina-S ± Bevacizumab Versus Investigator's Choice of Platinum-Based Chemotherapy ± Bevacizumab as 2L Treatment in Participants With Recurrent Platinum-Sensitive Ovarian Cancer

Singapore, Sept. 21 -- The Health Sciences Authority received information related to the study titled 'A Randomized, Open-label, Phase 3 Study of Rina-S ± Bevacizumab Versus Investigator's Choice of P... Read More

Singapore Clinical Trial: ROSETTA Lung-201: A Randomized, Multicenter, Open-label Phase 3 Study of Pumitamig Monotherapy Compared to Durvalumab in Participants with Unresectable Stage III NSCLC Without Progression After Platinum-based Concurrent Chemoradiation Therapy.

Singapore, Sept. 21 -- The Health Sciences Authority received information related to the study titled 'ROSETTA Lung-201: A Randomized, Multicenter, Open-label Phase 3 Study of Pumitamig Monotherapy Co... Read More

Singapore Clinical Trial: A Phase 2, Randomized, Open-Label Study of VVD-133214 in Combination with Pembrolizumab compared with Pembrolizumab monotherapy in participants with advanced colorectal adenocarcinoma (CRC) harboring microsatellite instability (MSI) and/or deficient mismatch repair (DMMR)

Singapore, Sept. 21 -- The Health Sciences Authority received information related to the study titled 'A Phase 2, Randomized, Open-Label Study of VVD-133214 in Combination with Pembrolizumab compared ... Read More

Singapore Clinical Trial: A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Investigator Choice of Chemotherapy (modified FOLFIRINOX or Gemcitabine plus Nab-paclitaxel) with or without Zoldonrasib (RMC 9805) as First-line Treatment in Patients with Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma (RASolute 305)

Singapore, Sept. 21 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Investigator Choice of Chemother... Read More

Singapore Clinical Trial: A Phase 1, Investigator- and Participant-Blinded, Placebo-Controlled, Randomized, Multiple-Dose Study to Evaluate the Gastric Emptying Delay, Pharmacokinetics, Safety, and Tolerability of Eloralintide in Participants with Obesity or Overweight

Singapore, Sept. 21 -- The Health Sciences Authority received information related to the study titled 'A Phase 1, Investigator- and Participant-Blinded, Placebo-Controlled, Randomized, Multiple-Dose S... Read More

IPS Academy Hosts Five-Day Induction Programme 'Aavahan 2026' at North Campus

New Delhi, Sept. 21 -- Indore (Madhya Pradesh) [India], September 19: IPS Academy, Indore-Ujjain Road North Campus , organised the five-day induction and orientation programme "Aavahan... Read More

As key DPDP compliance milestones approach, 250 founders and 35 investors gather in Bengaluru to make privacy a growth strategy

Bhubaneswar, Sept. 21 -- The DPDP Zone summit drew 350 attendees, including 250 founders, while 15 startups pitched at an invite-only Demo Session. Bengaluru, 21 September 2026: DPDP Zone's Privacy b... Read More

• ««
• «
• 8150
• 8151
• 8152
• 8153
• 8154
• 8155
• 8156
• 8157
• 8158
• 8159
• »
• »»